Category: MS Drug Therapies

Featured image for “Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis”

Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis

September 2, 2024 • In the HERCULES study, tolebrutinib met the primary endpoint in delaying time to onset of confirmed…

Stuart Schlossman

Featured image for “Why BOTHER taking MS Medications?”

Why BOTHER taking MS Medications?

No excerpt…

Stuart Schlossman

Featured image for ““MS101, The Basics” with Aaron Boster, MD”

“MS101, The Basics” with Aaron Boster, MD

At the 2024 MS WELLNESS SUMMIT, Doctor Aaron Boster, MD an MS Neurologist, discusses his 6-for-6 for YOUR care in…

Stuart Schlossman

Featured image for “Prescription Assistance”

Prescription Assistance

If you need help paying for your medication, our guide can help you find the right assistance. This guide was…

Stuart Schlossman

Different lymphocyte counts of ms patients treated with ofatumumab and ocrelizumab

Christoph Friedli 1 2, Nik Krajnc 3 4, Helly N Hammer 1, Stefanie Marti 1, Tobias Zrzavy 3 4, Maria E Evangelopoulos 5, Ioanna Kapsali 5, Paulus Rommer 3 4, Thomas Berger 3 4, Andrew Chan 1, Gabriel Bsteh 3 4, Robert Hoepner 1 Affiliations expand Abstract Introduction: Patients with Multiple…

Stuart Schlossman

Featured image for “Breaking news: Committee favors approval of under-the-skin Ocrevus in Europe”

Breaking news: Committee favors approval of under-the-skin Ocrevus in Europe

By: Andrea Lobo, PhD — Written – April 30, 2024 New formulation recommended by CHMP would be faster, easier for…

Stuart Schlossman

Featured image for “Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)”

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)

April 17, 2024 Download PDF New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis…

Stuart Schlossman

Featured image for “Press Release: TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis”

Press Release: TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

Apr 18, 2024 PDF Version NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), announced that…

Stuart Schlossman

Featured image for “Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis”

Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis

Apr 17, 2024 EAST HANOVER, N.J., April 17, 2024 — Novartis today announced data from the ALITHIOS open-label extension study showing sustained…

Stuart Schlossman

Apr 16, 2024 – Press Release: Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Media / Press Releases Tuesday, Apr 16, 2024 Results from the Phase III study showed that subcutaneous (SC) injection was consistent with…

Stuart Schlossman

Categories

Latest Blog Posts